Corporate & Securities

Joint Ventures, Strategic Alliances, Collaborations & Technology Transfer

When thinking about entering into a partnership to develop your company or your product line, it’s crucial to consider the business, financial, and legal implications. Whether you are a company or individual in the life sciences or technology industry, you need counsel who is familiar with the ins and outs of your business so you can benefit from the most solidly structured agreement possible.

Our attorneys are regarded as some of the most knowledgeable attorneys in negotiating agreements for joint venture and collaborative research; development, services, and university licensing arrangements; and other agreements to develop new products and technology. Our attorneys’ knowledge of business, communications, technology, and intellectual property law allows them to provide exceptional business-focused legal advice in these complicated transactions. We will work closely with you to structure and implement a transaction that builds upon your strengths and fills the gaps where needed.

Quick Facts

  • National Tier 1 ranking for Technology Law and Biotechnology Law by US News & World Report and Best Lawyers in “Best Law Firms” (2014)
  • Integrated intellectual property, licensing, and corporate practice
  • "Licensing and Collaborations Firm of the Year" by LMG Life Sciences (2013)
  • Assist clients in bringing their products from the research laboratory to the commercial market
  • Structure and implement technology-based transactions
  • Dozens of licensing / collaboration transactions since 2012, with an aggregate deal value of close to $5 billion

Areas of Focus

  • Advertising issues
  • Business continuity and master recovery
  • Data security and privacy
  • Development and collaboration arrangements
  • Distributorship agreements
  • Establishment, sourcing, procurement, and Implementation of IT systems and services
  • In-licensing of technology from universities and research institutions
  • Intellectual property protection and enforcement programs
  • Internet transactions and Internet liability issues
  • Outsourcing transactions
  • Strategic alliances and joint ventures

Sort by: Name  Title  Office

Representative Experience

  • Represented Inhibrx LLC in its June 2012 Option and License Agreement with Celgene Corporation.
  • Represented GreatPoint Energy, Inc. in its $400 million Series D financing led by China Wanxiang Holding Co. Ltd.
  • Represented Angiochem, Inc. in its February 2012 collaboration with GlaxoSmithKline (GSK).
  • Represented Intarcia Therapeutics, Inc. in its December 2011 strategic alliance with Quintiles.
  • Represented ArQule, Inc. (NASDAQ: ARQL) in the November 2011 execution of a license agreement with Daiichi Sankyo, Co. Ltd.
  • Represented BeiGene, LLC on the exclusive in-licensing and co-development agreements of October 2011 with Janssen Pharmaceutica NV and CNA Development, LLC, divisions of Johnson & Johnson (NYSE: JNJ).